To Order: patrick@cotinis.com
CD16 Antibody |
|||
| DF7007 | Affbiotech | 200ul | EUR 420 |
CD16 antibody |
|||
| 10R-6359 | Fitzgerald | 100 ug | EUR 249.6 |
|
Description: Mouse monoclonal CD16 antibody |
|||
CD16 antibody |
|||
| 10R-CD16bHU | Fitzgerald | 100 ug | EUR 1364.4 |
|
Description: Mouse monoclonal CD16 antibody |
|||
CD16 antibody |
|||
| 10R-CD16cHU | Fitzgerald | 100 ug | EUR 379.2 |
|
Description: Mouse monoclonal CD16 antibody |
|||
CD16 antibody |
|||
| 10R-CD16DHU-S | Fitzgerald | 100 ug | EUR 226.8 |
|
Description: Mouse anti-Human Monoclonal CD16 antibody |
|||
CD16 antibody |
|||
| 10R-CD16gMS | Fitzgerald | 500 ug | EUR 444 |
|
Description: Rat monoclonal CD16 antibody |
|||
CD16 Antibody |
|||
| RQ4193 | NSJ Bioreagents | 100 ug | EUR 419 |
Cd16 Antibody |
|||
| RQ6092 | NSJ Bioreagents | 100 ug | EUR 419 |
|
Description: Low affinity immunoglobulin gamma Fc region receptor III-A is a protein that in humans is encoded by the FCGR3A gene. This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Cd16 Antibody |
|||
| RQ6627 | NSJ Bioreagents | 100ug | EUR 419 |
|
Description: Fc receptors bind the most common class of antibody, IgG, are called Fc gamma receptors (FcgR). FcgR is divided into three classes, Fc gamma RI (CD64), Fc gamma RII (CD32), and Fc gamma RIII (CD16). CD16 protein is a multifunctional, low/intermediate affinity receptor, which belongs to the immunoglobulin superfamily. It is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. Mouse CD16 is encoded by a single gene, while, human CD16 is expressed as two distinct forms (CD16a/FcgRIIIa and CD16b/FcgRIIIb) encoded by two different highly homologous genes in a cell type-specific manner. CD16 is involved in phagocytosis, secretion of enzymes, inflammatory mediators, antibody-dependent cellular cytotoxicity (ADCC), and clearance of immune complexes. |
|||
CD16 Antibody |
|||
| V2499-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Recognizes a protein of 50-65 kDa, identified as CD16 (Workshop IV; Code N39 ) (also known low affinity Fc receptor III for IgG (FcRIII) or Leu 11). CD16 exists as a polypepetide-anchored from (FCRIIIA or CD16A) on human natural killer (NK) cells and monocytes/ macrophages and as a glycosylphosphatidylinositol (GPI)-anchored form (FcRIIIB or CD16B) on neutrophils. CD16B is polymorphic and the two alleles are termed NA1 and NA2.3 CD16 plays a role in signal transduction, NK cell activation and antibody-dependent cellular cytotoxicity. This mAb has been showed to inhibit the binding of immune complex to NK cells, inhibit cytotoxicity of NK cells, and induce calcium fluxes in NK cells and neutrophils. |
|||
CD16 Antibody |
|||
| V2499-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Recognizes a protein of 50-65 kDa, identified as CD16 (Workshop IV; Code N39 ) (also known low affinity Fc receptor III for IgG (FcRIII) or Leu 11). CD16 exists as a polypepetide-anchored from (FCRIIIA or CD16A) on human natural killer (NK) cells and monocytes/ macrophages and as a glycosylphosphatidylinositol (GPI)-anchored form (FcRIIIB or CD16B) on neutrophils. CD16B is polymorphic and the two alleles are termed NA1 and NA2.3 CD16 plays a role in signal transduction, NK cell activation and antibody-dependent cellular cytotoxicity. This mAb has been showed to inhibit the binding of immune complex to NK cells, inhibit cytotoxicity of NK cells, and induce calcium fluxes in NK cells and neutrophils. |
|||
CD16 Antibody |
|||
| V2499SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Recognizes a protein of 50-65 kDa, identified as CD16 (Workshop IV; Code N39 ) (also known low affinity Fc receptor III for IgG (FcRIII) or Leu 11). CD16 exists as a polypepetide-anchored from (FCRIIIA or CD16A) on human natural killer (NK) cells and monocytes/ macrophages and as a glycosylphosphatidylinositol (GPI)-anchored form (FcRIIIB or CD16B) on neutrophils. CD16B is polymorphic and the two alleles are termed NA1 and NA2.3 CD16 plays a role in signal transduction, NK cell activation and antibody-dependent cellular cytotoxicity. This mAb has been showed to inhibit the binding of immune complex to NK cells, inhibit cytotoxicity of NK cells, and induce calcium fluxes in NK cells and neutrophils. |
|||
CD16 Antibody |
|||
| V2500-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes CD16 (Fcgamma;RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fcgamma;RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fcgamma;RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V2500-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: It recognizes CD16 (Fcgamma;RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fcgamma;RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fcgamma;RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V2500SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes CD16 (Fcgamma;RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fcgamma;RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fcgamma;RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V2501-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes CD16 (Fcgamma;RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fcgamma;RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fcgamma;RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V2501-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: It recognizes CD16 (Fcgamma;RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fcgamma;RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fcgamma;RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V2501SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: It recognizes CD16 (Fcgamma;RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fcgamma;RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fcgamma;RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V8858-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: It recognizes CD16 (Fc gamma RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fc gamma RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fc gamma RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V8858-20UG | NSJ Bioreagents | 20ug | EUR 219 |
|
Description: It recognizes CD16 (Fc gamma RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fc gamma RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fc gamma RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 Antibody |
|||
| V8858SAF-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: It recognizes CD16 (Fc gamma RIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (Fc gamma RIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (Fc gamma RIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. |
|||
CD16 |
|||
| 16A2-100T | ImmunoStep | 100 test | EUR 512.4 |
CD16 |
|||
| 16B2-01MG | ImmunoStep | 100 test | EUR 340.8 |
CD16 |
|||
| 16CFB2-100T | ImmunoStep | 100 test | EUR 465.6 |
CD16 |
|||
| 16F-100T | ImmunoStep | 100 test | EUR 356.4 |
CD16 |
|||
| 16F2-100T | ImmunoStep | 100 test | EUR 372 |
CD16 |
|||
| 16PE2-100T | ImmunoStep | 100 test | EUR 418.8 |
CD16 |
|||
| 16PP2-100T | ImmunoStep | 100 test | EUR 684 |
CD16 |
|||
| 16PU-01MG | ImmunoStep | 0,1 mg | EUR 262.8 |
CD16 |
|||
| 16PU2-01MG | ImmunoStep | 0,1 mg | EUR 262.8 |
CD16(HuNK2) Antibody |
|||
| BNCA0928-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD16(HuNK2), APC conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCA1056-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD16(HO80), APC conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCAP0928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCAP0928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCAP1056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCAP1056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC610928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC610928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC611056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC611056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNUM0928-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against CD16(HuNK2), 1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNUM1056-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against CD16(HO80), 1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCR0928-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD16(HuNK2), RPE conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCR1056-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD16(HO80), RPE conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNUB0928-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against CD16(HuNK2), Concentration: 0.2mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNUB0928-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against CD16(HuNK2), Concentration: 0.2mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNUB1056-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against CD16(HO80), Concentration: 0.2mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNUB1056-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against CD16(HO80), Concentration: 0.2mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC430928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC430928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC431056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC431056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC051056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC051056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC400928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC400928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC401056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC401056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC810928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC810928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC811056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC811056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC880928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC880928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC881056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC881056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC800928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC800928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC801056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC801056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCH0928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCH0928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCH1056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCH1056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCP0928-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD16(HuNK2), PerCP conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCP1056-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD16(HO80), PerCP conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC041056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC041056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC050928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC050928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC680928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC680928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC681056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC681056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC700928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC700928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC701056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC701056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCB0928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNCB0928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCB1056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNCB1056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC940928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC940928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC941056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC941056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC550928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC550928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC551056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC551056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC470928-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HuNK2), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HuNK2) Antibody |
|||
| BNC470928-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HuNK2), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC471056-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD16(HO80), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD16(HO80) Antibody |
|||
| BNC471056-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD16(HO80), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD16 Monoclonal Antibody |
|||
| EM1090-100ul | ELK Biotech | 100ul | EUR 334.8 |
|
Description: A Mouse Monoclonal antibody against CD16 from Human. This antibody is tested and validated for WB, ELISA, IHC, Flow Cyt |
|||
CD16 Monoclonal Antibody |
|||
| EM1090-50ul | ELK Biotech | 50ul | EUR 248.4 |
|
Description: A Mouse Monoclonal antibody against CD16 from Human. This antibody is tested and validated for WB, ELISA, IHC, Flow Cyt |
|||
CD16 antibody (biotin) |
|||
| 61R-1476 | Fitzgerald | 100 ug | EUR 360 |
|
Description: Mouse monoclonal CD16 antibody (biotin) |
|||
CD16 antibody (FITC) |
|||
| 61R-CD16aHUFT | Fitzgerald | 100 tests | EUR 571.2 |
|
Description: Mouse monoclonal CD16 antibody (FITC) |
|||
CD16 antibody (PE) |
|||
| 61R-CD16cHUPE | Fitzgerald | 120 tests | EUR 716.4 |
|
Description: Mouse monoclonal CD16 antibody (PE) |
|||